BioRestorative Therapies, Inc. (BRTX)
1.46
-0.04
(-2.67%)
USD |
NASDAQ |
Oct 15, 16:00
1.43
-0.03
(-2.05%)
After-Hours: 20:00
BioRestorative Therapies Cash from Operations (TTM) : -11.82M for March 31, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | -11.82M |
| December 31, 2025 | -10.79M |
| September 30, 2025 | -10.72M |
| June 30, 2025 | -9.520M |
| March 31, 2025 | -8.691M |
| December 31, 2024 | -8.230M |
| September 30, 2024 | -7.470M |
| June 30, 2024 | -6.950M |
| March 31, 2024 | -6.369M |
| December 31, 2023 | -6.430M |
| September 30, 2023 | -6.416M |
| June 30, 2023 | -6.688M |
| March 31, 2023 | -6.655M |
| December 31, 2022 | -5.871M |
| September 30, 2022 | -5.442M |
| June 30, 2022 | -4.620M |
| March 31, 2022 | -4.111M |
| December 31, 2021 | -3.330M |
| September 30, 2021 | -2.757M |
| June 30, 2021 | -2.651M |
| March 31, 2021 | -2.329M |
| December 31, 2020 | -1.964M |
| September 30, 2020 | -3.203M |
| June 30, 2020 | -4.391M |
| March 31, 2020 | -5.387M |
| Date | Value |
|---|---|
| December 31, 2019 | -6.919M |
| September 30, 2019 | -6.661M |
| June 30, 2019 | -6.303M |
| March 31, 2019 | -5.927M |
| December 31, 2018 | -5.105M |
| September 30, 2018 | -4.911M |
| June 30, 2018 | -4.068M |
| March 31, 2018 | -3.793M |
| December 31, 2017 | -3.854M |
| September 30, 2017 | -3.556M |
| June 30, 2017 | -4.252M |
| March 31, 2017 | -4.504M |
| December 31, 2016 | -5.003M |
| September 30, 2016 | -4.995M |
| June 30, 2016 | -4.373M |
| March 31, 2016 | -4.165M |
| December 31, 2015 | -3.122M |
| September 30, 2015 | -2.702M |
| June 30, 2015 | -2.952M |
| March 31, 2015 | -3.096M |
| December 31, 2014 | -3.228M |
| September 30, 2014 | -3.357M |
| June 30, 2014 | -2.958M |
| March 31, 2014 | -2.707M |
| December 31, 2013 | -2.672M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Myriad Genetics, Inc. | 7.70M |
| CareDx, Inc. | 93.66M |
| Natera, Inc. | 228.24M |
| Exagen, Inc. | -6.498M |
| Sera Prognostics, Inc. | -27.68M |